The nearly $185 million legal bill C.R. Bard Inc. (NYSE:BCR) paid to settle most of the lawsuits against subsidiary Davol Inc.’s hernia repair products pushed the company into the red during the second quarter and sent its share price tumbling on Wall Street today.
The Murray Hill, N.J.-based company reported a $47.8 million loss on $725 million in sales during the three month period ended June 30, 2011, reversing a $124.7 million profit on $673.9 million in sales the company reported during the same period last year.
Taking out the $184 million legal settlement, the company would have posted 141.7 million in net income , officials said in a prepared release.
On Wall Street, shares of BCR dropped nearly 12 percent from yesterday’s closing price of $112.71.
In late June, the company said it would settle most of the lawsuits against its Davol, Inc. subsidiary.
Through late last year, more than 2,700 plaintiffs had filed suit in either federal or state courts pursuing product-liability claims for personal injuries, with most of those cases since transferred to the U.S. District Court for Rhode Island.
Warwick, R.I.-based Davol Inc. subsidiary, began a recall of its Composix Kugel hernia patches in December, 2005, after receiving reports that the device broke apart inside several patients.
A recoil ring used to secure the mesh patch to tissue perforations separated and, in some cases, began to move throughout the abdomen, damaging internal organs. Many other patients reported severe pain or other complications following repair surgery.
Bard refuted most of the claims, saying it acted responsibly and began the recall voluntarily as soon as troubles with the Composix patch surfaced. But the company also butted heads with insurance carriers, some of which balked at paying claims against Bard’s product-liability policies.
In January 2010 Bard announced that an unnamed insurance carrier agreed to again cover potential claims resulting from ongoing litigation. In exchange for securing coverage up to a non-disclosed limit, Bard agreed to quit seeking payment of money it claimed the insurance company owed and will instead take a $25 million, pre-tax write-off.
In August 2010, a North Carolina couple won $1.5 million in a lawsuit against Bard.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.